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ABSTRACT
Patien ts  w ith familial male-limited precocious puberty present 
with early onset of puberty. Several missense m utations in the LH 
receptor gene th a t cause amino acid substitu tions in the sixth tran s­
membrane segment of the  receptor pi'otein have been shown to be a 
cause of the disorder. We have identified a novel LH receptor gene 
m utation in  a patien t w ith familial male-limited precocious puberty 
th a t results in a threonine for m ethionine substitution a t  position 398 
in the second transm em brane segm ent of the receptor protein. In  vitro 
expression in hum an embryonic kidney 293 cells of this LH receptor 
m utan t and two previously described LH receptor m utants showed
th a t  cAMP production in the absence of hormone was elevated up to 
25-fold compared to the basal level of the wild-type receptor. The EDn() 
values of hormone-induced cAMP production were within the same 
range for wild-type and m u tan t receptors, but maximal hormone- 
induced cAMP production was relatively low for m utan t receptors. We 
also produced receptors containing amino acid substitutions in both 
the second and sixth transm em brane segments. For these double 
m utants, basal receptor activities were similar to the basal activities 
observed in single m utants, whereas hormone-induced receptor ac­
tivation was almost completely abolished. (J  Clin Endocrinol Metah 
80: 3168-3172, 1995)
RECEPTORS for LH a  2), TSH (3), and FSH (4) form asubgroup of glycoprotein hormone receptors within 
the family of GTP-binding protein (G protein)-coupled re­
ceptors. Receptors of this family are characterized by a trans­
membrane domain, an N-terminal extracellular domain, and 
a C-terminal intracellular domain. Most G protein-coupled 
receptors contain a short extracellular domain that does not 
seem to have a specific function. In contrast, glycoprotein 
hormone receptors contain a large extracellular domain of 
approximately the same size as the transmembrane domain 
that is involved in high affinity hormone binding (5).
The transmembrane domain of G protein-coupled recep­
tors consists of seven transmembrane segments, connected 
by three intra- and three extracellular loops. This domain 
anchors the receptor in the plasma membrane and is in­
volved in ligand binding and receptor activation. Construc­
tion and expression of chimeric adrenergic receptors, in 
which domains of a2- and j32-adrenergic receptors were ex­
changed, showed that most of the seven transmembrane 
segments are involved in specific agonist ligand binding, 
whereas the seventh segment is the major determinant for 
antagonist specificity (6). More subtle swapping experi­
ments, in which small parts of the third intracellular loop 
were exchanged between different adrenergic receptors,
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have shown that this loop is involved in specific G protein 
coupling and activation [reviewed by Dohlman ct nL (7)]. 
Substitution of the alanine 293 residue located in this third 
intracellular loop of the a1B-adrenergic receptor by any other 
amino acid residue resulted in elevated basal receptor ac­
tivities (8). These results indicate that the receptor resides in 
an inactive conformation that can be released after confor­
mational changes induced by either interaction of the ligand 
with the transmembrane domain or amino acid substitutions 
in the transmembrane domain. For glycoprotein hormone 
receptors, the transmembrane domain by itself is not an 
important high affinity hormone-binding domain, and hor­
mone-induced conformational changes may result from in­
teractions of the large extracellular domain and/or the 
bound hormone with the transmembrane domain (5).
Mutagenesis is an important tool to investigate the struc- 
ture-function relationship of G protein-coupled receptors. 
Another approach to characterize domains important for 
receptor function is to study diseases caused by receptor 
gene mutations. Patients with the syndrome of familial male- 
limited precocious puberty (FMPP) have LIT receptor gene 
mutations (9-12). FMPP is an autosomal dominant condi­
tion. Affected boys present with early onset of puberty 
caused by a gonadotropin-independent stimulation of tes­
ticular androgen production (13). The LH receptor gene mu­
tations identified in FMPP patients result in amino acid sub­
stitutions in the sixth transmembrane segment of the receptor 
protein. In vitro expression of these mutant receptors in COS
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cells revealed constitutively activated receptors in terms of 
increased basal cAMP production (10), whereas basal inositol 
phosphate production and hormone binding affinity were 
comparable to those of the wild-type receptor (11,12). This 
elevated basal receptor activity that stimulates cAMP pro­
duction is most likely the cause of autonomous steroid pro­
duction in these FMPP patients* The location of the amino 
acid substitutions near the third intracellular loop suggests 
mutational induction of conformational changes similar to 
those induced in the mutated a1B-adrenergic receptor, which 
partially release the LIT receptor from its inactive conforma­
tion,
In the present paper, we report a new FMPP family car­
rying a LH receptor gene mutation that, in contrast to the 
thus far identified mutations, results in a receptor-activating 
amino acid substitution in the second transmembrane seg­
ment of the receptor protein.
M aterials and Methods
Patients
The patient was referred at the age of 2 yr, 9 months, because of 
progressive sexual development. Serum LH and FSH levels were in the 
prepubertal range and did not rise after stimulation with GnRH, Serum 
testosterone was elevated to pubertal levels (22.5 nmol/L; normal pre­
pubertal levels, <0.1 nmol/L). The patient's mother and sister were 
normal; however, the father had also developed pubertal signs at an 
early age. Informed consent was obtained from each subject or his 
parents.
Patients in whom the Met*71—»lie and Asp 57H Gly substitutions
were identified have been described by Kremer ct nl. (9).
DNA analysis
isolation of genomic DNA, polymerase chain reaction (PCR) DNA 
amplification, single strand conformational polymorphism (SSCP), and 
sequence analysis were performed as described before (9), with the 
exception that for the SSCP, PCR amplification was performed with one 
labeled primer. Subjects were screened using several primer sets am­
plifying overlapping parts of the transmembrane domain. Primer set 2 
forward primer, 5' -ATGACTGTTCTTTTTGTTCTCCTG-3'; reverse 
primer, 5'-GGTCCAGGTGAATAGCATAGG-3'; amplifying fragment, 
1132-1426; numbering according to Minegishi cl nl. (14)] gave rise to an 
abnormally migrating band. This fragment was subjected to sequence 
analysis,
Construction of m utant L H  receptor expression plasmids
Standard molecular biology techniques were performed as described 
by Sambrook ct nl, (15), A wild-type human LH receptor expression 
plasmid (pSG5-hLHR) was constructed by cloning the human LH re­
ceptor complementary DNA (nucleotides —3 to 2374 relative to the 
translation start site) into the EcoRI site of pSG5 (16). The protein en­
coded by this complementary DNA differs from the published human 
LH receptor (14) by the insertion of two amino acids (Leu and Gin) at 
positions 21 and 22 (not shown). Mutations were introduced into this 
plasmid by site-directed mutagenesis (17), using PCR DNA amplifica-
tion techniques. For substitutions Met.571 lie and Asp57B Gly, a 300-
base pair (bp) fragment (1512-1812) was amplified using primers
LI-IR1512FOR (5'-GTCGGTGTCAGCAATTAC-3') and LHR1812REV 
(5'-GGTTACTGTGATAAGAGG-3'). Mutations were introduced dur­
ing two rounds of amplification using primers LHR571MIFOR (5'- 
GCTA AG A A A AT AGC A ATCC-3 ' ) and LHR571M1REV (5'-GGATTGC- 
TATTTTCTTAGC-3') for the Met57,~>Ile substitution, and LHR578- 
DGFOR (5,-CTTCACCGGTTTCACCTG-3#) and LHR578DGREV (5'-
1744), and the resulting fragments were exchanged into the wild-type 
LH receptor expression plasmid, yielding pSG5-LHRl and pSG5-LHR2, 
respectively. For the Met398—>Thr substitution, a 400-bp fragment (1030— 
1430) was amplified using primers LHR1030FOR (5'-CCGATGTGCTC- 
CTGAACC-3') and LHR1430REV (5'-GTCCAGGTGAATAGCATAG- 
3'). The mutation was introduced using primers LHR398MTFOR (5'- 
CGTTTTCTCACGTGCAATC-3') and LHR398MTREV <5'-GATTGC~ 
ACGTGAGAAAACG-3'). The amplified DNA was digested w ith £tew36I 
and Xbal (positions 1090 and 1390), and the resulting fragment was 
exchanged for the wild-type LH receptor expression vector, yielding 
pSG5-LHR3. Primers were purchased from Eurogentec (Seramg, Bel­
gium). Mutagenesis was verified by sequence analysis of the exchanged 
fragments. Double mutants were constructed by exchanging the 1173-bp 
Xbal fragment from pSG5-LHRl and pSG5-LHR2 in pSG5-LHR3, yield­
ing pSG5-LIiR31 and pSG5-LHR32, respectively. For transfection 
purposes, plasmids were isolated using a Plasmid Maxi Kit (Qiagen, 
Düsseldorf, Germany).
In  vitro expression o f m u tan t L H  I'eceptors in HEK293 cells
Human embryonic kidney 293 cells (American Type Culture Collec­
tion designation CRL 1573, Rockville, MD) were maintained in Dulbec- 
co's Modified Eagle's M edium-Ham's F-12  medium (1:1, vol/vol; 
GIBCO BRL, Gaithersburg, MD) containing 10% (vol/vol) fetal calf 
serum (SEBAK, Aidenbach, Germany), 2 X 10^ IU /L  penicillin (Brocades 
Pharma, Leiderdorp, The Netherlands), and 0.2 g /L  streptomycin (Ra­
dium Farma, Milan, Italy). Cells were seeded at 10% confluence, incu­
bated in a humidified incubator at 37 C and 5% C 0 2, and split at 50-70% 
confluence.
One day before transfection, cells were seeded at 15-20% confluence 
in 12-well plates (Costar, Cambridge, MA). C aP 04 precipitate transfec­
tions were performed as previously described (18). Each well received 
50 juL CaPO„ precipitate, containing 0.5 ¡xg expression plasmid, 0.1 (Mg 
pRSVluc (19) as an internal control, and 0.4 fAg pTZ19R (Pharmacia, 
Uppsala, Sweden) as carrier DNA. Forty-eight hours after transfection, 
cells were washed with medium without serum, but containing 25 
m m ol/L  HEPES (GIBCO), 0.1% (wt/vol) BSA, and 0.2 m m ol/L  isobu- 
fcylmethylxan thine (Sigma Chemical Co., St, Louis, MO), and subse­
quently incubated for 2 h in the same medium containing different doses 
of hCG (urinary hCG; Organon International, Ohs, The Netherlands). 
Medium was collected for cAMP determination (20), and cells were 
lysed for luciferase activity determination (21). Values for cAMP were 
corrected by subtracting control cAMP levels, as determined in cells 
transfected with empty expression vector (pSG5). Control cAMP levels 
were approximately 50% of basal levels in wild-type LH receptor-trans­
fected cells, The cAMP values were corrected for transfection efficiency 
using theluciferase activity in the same well, yielding cAMP production 
in picomoles per relative light unit.
CAGGTGAAACCGGTGAAG-3') for the AspJ37B Gly substitution. The
Results
Identification o f a new L H  receptor missense m utation in a 
FMPP family
A family in which both father and son showed clinical 
symptoms of the FMPP syndrome was screened for muta­
tions in the LH receptor gene. Overlapping DNA fragments 
encoding parts of the transmembrane domain were ampli­
fied and subjected to SSCP analysis. A primer set amplifying 
the second transmembrane segment gave rise to abnormally 
migrating bands for the father and son, but not for the mother 
or four control subjects (Fig. 1A). DNA sequence analysis of 
this fragment revealed a heterozygous T to C conversion at 
position 1193 relative to the translation start site in both the 
father and the son (Fig. IB). This mutation causes a threonine 
for methionine substitution at position 398 (Met398—>Thr), 
which is located in the second transmembrane segment of the
amplified DNA was digested with BstXI and BspM.1 (positions 1550 and receptor protein.
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F ig. 1. Identification of a missense m uta tion  in  the  LH receptor gene, 
A, SSCPs for the LH receptor gene in  a FM PP family (father, mother, 
and son), For comparison, SSCP p a tte rn s  for norm al individuals (con­
trol) are shown on either side* Both fa ther an d  son show a slight 
mobility shift in  th is  fragment, B, Sequence analysis of the LH re ­
ceptor gene (from position 1187 to 1198, relative to the  translation 
start) in  a normal individual (control) and the  son from the FM PP 
family. A heterozygous T to C conversion is detected at position 1193. 
The father had the same m utation.
M utant receptors constitutively stim ulate cAMP production
Previously, we identified two other LH receptor gene mu­
tations in FMPP patients that result in amino acid substitu­
tions in the sixth transmembrane segment (Met571—>He and 
Asp —»Gly) (9), For these substitutions and for the newly 
identified Met398—»Thr substitution, mutant receptor expres­
sion plasmids were constructed and transiently expressed in 
HEK293 cells to test the effects of the substitutions on re­
ceptor function. Forty-eight hours after transfection, the cells 
were incubated in the absence or presence of different doses 
of hCG for 2 h. It was observed that stimulation of the mutant 
receptors with a high hCG concentration resulted in cAMP 
production at a level approximately 40% of that obtained 
with the wild-type LH receptor, whereas the EDS0 values 
were within the same range (3 ng/mL; Fig. 2A). However, 
basal levels of cAMP production in the absence of hCG were 
increased approximately 15- to 25-fold for cells expressing 
the mutant receptors compared to those in cells expressing 
the wild-type receptor.
Elevated basal cAMP production should result in elevated 
androgen production by Leydig cells from FMPP patients in 
the absence of LH. To test whether the mutant receptors are 
able to induce steroid production in the absence of gonado­
tropins, they were transiently expressed in mouse tumor 
Leydig cells (MA10). This indeed resulted in a 2- to 6-fold 
increase in pregnenolone production in the absence of hCG 
(data not shown)* Expression of the wild-type human LH 
receptor in these cells resulted in only a 1.5-fold increase in 
the absence of hCG.
Double mutants have the same effect on basal cAMP 
production as single mutants
The amino acid substitutions found in the second and sixth 
transmembrane segments resulted in similar effects on re­
ceptor function. Substitutions in both transmembrane seg­
ments might act in an independent fashion, i.e. induction of 
conformational changes in each transmembrane segment 
may release separate domains for G protein activation from 
their inactive conformation. LH receptors containing substi-
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F ig . 2. Dose-response relationships of hCG-induced cAMP production by wild-type and m utant LH receptors. Receptors were transiently 
expressed in  HEK293 cells, and  cAMP production was determined as described in Materials and Methods. Each poin t  represents the mean ± 
SEM for three replicate wells from a single experiment, Results were similar in three different experiments. A, Single amino acid substitutions.
O, Wild type; • ,  M et571—> lie; A, Asp578—»Gly; ■, M et398—>Thr. B, Double amino acid substitutions. O, Wild type; ♦ ,  Met,19H—>Thv and 
M etG7L—»lie; V, M et398—»Thr and AspR78~*Gly.
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398 Thr and Asp 578
dig cells (23). Correction for transfection efficiency of the 
different expression plasmids by means of cotransfection 
with a luciferase expression plasmid does not result in equal 
numbers of binding sites on the plasma membrane. This 
implies that the amino acid substitutions change not only 
Gly. These double mutants basal receptor activity, but also posttranslational modifica-
tutions in both segments then might exhibit higher or even 
additive basal activities.
To test this hypothesis, double mutant receptor expres­
sion plasmids were constructed containing both substitu­
tions Met398—>Thr and Met571—>lie or both substitutions
Met
were transiently expressed in HEK293 cells, and basal and 
hCG-induced cAMP productions were determined. It was 
found that these double mutants show little hCG-induced 
cAMP production, and the basal levels of cAMP produc­
tion in the absence of hCG were increased up to 10- to 
15-fold the level observed in cells expressing the wild-type 
receptor (Fig. 2B). These results indicate that substitutions 
in the second and sixth transmembrane segments do not 
act independently.
Discussion
The present paper describes a new LH receptor gene mu­
tation that causes an amino acid substitution in the second 
transmembrane segment, in contrast to the previously re­
ported LH receptor mutations that change the sixth trans­
membrane segment (9-11). In vitro expression studies of this 
LH receptor mutant and two previously described mutants 
show elevated cAMP levels in the absence of hormone and 
approximately 60% reduction of their activities at maximal 
doses of hCG. In vitro expression of the mutant receptors in 
MA10 mouse tumor Leydig cells, which also express the 
wild-type LH receptor, resulted in a 2- to 6-fold, increase in 
basal steroid production. The phenotypes of the mutant re­
ceptors in HEK293 and MA10 cells and the genetic analysis 
(9) indicate that these mutations are most likely the cause of 
precocious puberty in FMPP boys.
The low response of the mutant receptors to high doses of 
hCG is different from results described by other investigators 
(10-12), who reported in vitro expression studies on 
Asp578—»dy, Thr —> lie, and Met571—>Ile mu tant LH recep­
tors. They found elevated cAMP production levels in the 
absence of hormone for the mutant receptors, but a response 
to high hormone concentrations similar to that of the wild-
'1 P*
type receptor. In one study, maximal [* I]hCG binding to 
cells expressing mutant receptors reached only 66% of the 
level found in cells expressing the wild-type receptor, 
whereas maximal hCG-induced cAMP production levels 
were identical for mutant and wild-type receptors (12). A 
reason for this discrepancy may be found in the very high 
expression levels that can be reached in the COS-7 cells used 
in these studies. Duprez ct a l  (22) showed that transfection 
of increasing amounts of TSH receptor expression plasmid 
into COS-7 cells leads to saturating expression of TSH re­
ceptors in the plasma membrane. Full stimulation of such 
cells may result in a plateau level of the maximal cAMP 
response because the numbers of G proteins and/or adenylyl 
cyclase proteins are limited; thus, not all occupied receptors 
can interact in an efficient manner with the signal transduc­
tion cascade. In the present experiments, the expression lev­
els of wild-type Lli receptors in HEK293 cells ranged from 
3,000-30,000 hCG-binding sites/transfected, cell (data not 
shown), which is within the physiological range for rat Ley-
tions and transport»
All activating LH and TSH receptor mutations identified thus 
far cause changes in the transmembrane domain, with the sixth 
transmembrane segment and the third intracellular loop as the 
apparent mutational hotspots (9-12,22,24-26). Because these 
regions have been suggested to play an important role in G 
protein coupling (6), it may be suggested that the amino acid 
changes mimic the hormone-induced conformational shift to a 
certain extent. The location of substitutions in the second trans­
membrane segment of the LH receptor (this report) and the 
third and seventh transmembrane segments of the TSH recep­
tor (22) indicate that more segments of the transmembrane 
domain are involved in retaining the receptor in an inactive 
conformation. Therefore, it is likely that amino acid substitu­
tions in several of the seven transmembrane segments may be 
identified in new cases of syndromes involving activated G 
protein-coupled receptors. The structural alterations caused by 
the mutations are diverse; polar and charged amino acid res­
idues are replaced by nonpolar amino acid residues and vice 
versa, The positions of the side-chains relative to the pocket of 
the transmembrane domain or the other transmembrane seg­
ments are also diverse. It would be interesting to study whether 
amino acid substitutions affect the overall inactive conforma­
tion of the receptor in a nonspecific fashion or whether specific 
substitutions are required to activate the receptor.
Amino acid substitutions leading to more drastic conforma­
tional changes will probably result in inactivation of the recep­
tor. LH receptor double mutants, containing substitutions in 
both the second and the sixth transmembrane segments, show 
little hCG-induced cAMP production, although the basal re­
ceptor activities are comparable to those of the single mutants. 
Alterations in the double mutant receptors are probably more 
pronounced and may have a drastic effect on posttranslational 
modifications and intracellular transport of the protein, or they 
may disrupt the protein structure in such a way that hormone- 
induced receptor activation is abolished.
Recently, we identified an inactivating LH receptor mu­
tation in patients with Leydig cell hypoplasia (27), These 
46,XY individuals present with a female external phenotype, 
with abdominal testes, and without female internal sex or­
gans. Testes from these patients contain very few Leydig 
cells, and testosterone levels are low. The disorder appeared 
to be caused by a LH receptor gene mutation causing a 
proline for alanine substitution in the sixth transmembrane 
segment. This Ala5t>3—>Pro substitution renders the receptor, 
which is expressed on the plasma membrane, completely 
inactive even at high hCG concentrations. Another receptor- 
inactivating mutation has been described for the TSH recep­
tor in In/tfhyt mice (28). In this case a conserved proline 
residue in the fourth transmembrane segment was substi­
tuted by a leucine residue. These drastic changes (both in­
volving a proline residue) in the LH and TSH receptors may 
have comparable effects on protein structure, posttransla-
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tional modifications, and intracellular transport as the dou­
ble amino acid substitutions.
In the subfamily of glycoprotein hormone receptors, hor­
mone binding and receptor activation are probably sequen­
tial events. It is not likely that activating substitutions will be 
found in the large N-terminal extracellular domain, because 
this domain is involved mainly in hormone binding and 
probably in proper positioning of the hormone relative to the 
transmembrane domain. Such positioning may enhance the 
interaction of the hormone with the transmembrane domain. 
In fact, it has been reported that hCG can activate a truncated 
LH receptor lacking the extracellular domain (29), suggesting 
an interaction site for the hormone with the transmembrane 
domain. However, high concentrations of hCG  had to be 
used, and similar experiments with the TSH receptor did not 
result in receptor activation (30). The functional separation of 
hormone binding and receptor activation is in agreement 
with the observation that the mutant LH receptors described 
herein do not show a shift in the ED50 of hCG-stimulated 
cAMP production. In contrast, activating substitutions of the 
Q-adrenergic receptor do cause a shift in the ED50 to lower 
concentrations. This shift is proportional to the degree of 
receptor activation by the amino acid change, which corre­
lates very well with the fact that ligand-activated a1-adren- 
ergic receptors show a higher affinity for the ligand (8, 31).
In conclusion, an amino acid substitution in the second 
transmembrane segment of the LH receptor has been iden­
tified in FMPP patients. The effect of this substitution on 
basal receptor activity is identical to the effects of amino acid 
substitutions in the sixth transmembrane segment. This sug­
gests an important role for several segments of the trans­
membrane domain in receptor function.
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